Switch theme
Sign up to access all valuation multiples
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient’s fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The group has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
1994
1.1K+
LTM Revenue $373M
LTM EBITDA $128M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vitrolife has a last 12-month revenue (LTM) of $373M and a last 12-month EBITDA of $128M.
In the most recent fiscal year, Vitrolife achieved revenue of $372M and an EBITDA of $125M.
Vitrolife expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vitrolife valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $373M | XXX | $372M | XXX | XXX | XXX |
| Gross Profit | $223M | XXX | $221M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $128M | XXX | $125M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBIT | $84.3M | XXX | $81.6M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $54.9M | XXX | $52.9M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $84.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Vitrolife's stock price is SEK 155 (or $16).
Vitrolife has current market cap of SEK 21.0B (or $2.2B), and EV of SEK 21.9B (or $2.3B).
See Vitrolife trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.2B | XXX | XXX | XXX | XXX | $0.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Vitrolife has market cap of $2.2B and EV of $2.3B.
Vitrolife's trades at 6.1x EV/Revenue multiple, and 18.1x EV/EBITDA.
Equity research analysts estimate Vitrolife's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vitrolife has a P/E ratio of 39.5x.
See valuation multiples for Vitrolife and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 6.1x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 17.7x | XXX | 18.1x | XXX | XXX | XXX |
| EV/EBIT | 26.8x | XXX | 27.7x | XXX | XXX | XXX |
| EV/Gross Profit | 10.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 39.5x | XXX | 41.0x | XXX | XXX | XXX |
| EV/FCF | 33.7x | XXX | 31.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVitrolife's last 12 month revenue growth is 4%
Vitrolife's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Vitrolife's rule of 40 is -87% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vitrolife's rule of X is 45% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vitrolife and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -87% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vitrolife acquired XXX companies to date.
Last acquisition by Vitrolife was XXXXXXXX, XXXXX XXXXX XXXXXX . Vitrolife acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vitrolife founded? | Vitrolife was founded in 1994. |
| Where is Vitrolife headquartered? | Vitrolife is headquartered in Sweden. |
| How many employees does Vitrolife have? | As of today, Vitrolife has 1.1K+ employees. |
| Who is the CEO of Vitrolife? | Vitrolife's CEO is Ms. Bronwyn Brophy. |
| Is Vitrolife publicy listed? | Yes, Vitrolife is a public company listed on STO. |
| What is the stock symbol of Vitrolife? | Vitrolife trades under VITR ticker. |
| When did Vitrolife go public? | Vitrolife went public in 2001. |
| Who are competitors of Vitrolife? | Similar companies to Vitrolife include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Vitrolife? | Vitrolife's current market cap is $2.2B |
| What is the current revenue of Vitrolife? | Vitrolife's last 12 months revenue is $373M. |
| What is the current revenue growth of Vitrolife? | Vitrolife revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Vitrolife? | Current revenue multiple of Vitrolife is 6.1x. |
| Is Vitrolife profitable? | Yes, Vitrolife is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vitrolife? | Vitrolife's last 12 months EBITDA is $128M. |
| What is Vitrolife's EBITDA margin? | Vitrolife's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Vitrolife? | Current EBITDA multiple of Vitrolife is 17.7x. |
| What is the current FCF of Vitrolife? | Vitrolife's last 12 months FCF is $67.1M. |
| What is Vitrolife's FCF margin? | Vitrolife's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of Vitrolife? | Current FCF multiple of Vitrolife is 33.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
